Background/aims: The transcription factor NFĸB is a major mediator of lipopolysaccharide (LPS) signaling. We determined the role of NFĸB activation in regulatory changes of the P-glycoprotein (Pgp) drug efflux transporter at the blood-brain barrier (BBB) and proinflammatory cytokine receptors. Methods: We treated NFĸB knockout and wildtype mice with LPS or vehicle, obtained enriched cerebral microvessels, and determined target mRNA by qPCR for MDR1a/b, IL15RΑ, IL2 RΑ, IL2RΓ, LIFR, gp130, and TNFR1/2, and protein expression by western blotting for P-gp, IL15RΑ, IL2RΓ, LIFR, and gp130. Results: The effects of LPS on the transporters and cytokine receptors showed differences between wildtype and NFĸB knockout mice, and between mRNA and protein changes. NFĸB not only mediated the LPS-induced increase of MDR1b, IL2RΓ, and TNFR2 mRNA in the wildtype mice, but it showed opposite effects by elevating IL15RΑ and TNFR1 mRNA and decreasing IL2RΑ in the knockout mice. Although basal vinblastine uptake was unchanged in the NFĸB knockout mice, LPS induced an increase of the uptake (depressed efflux transport) greater than that seen in the wildtype mice, indicating that NFĸB helps to maintain Pgp efflux transporter function. Conclusion: The results show differential involvement of NFĸB signaling in response to LPS at the BBB.

Keywords:
Cerebral microvessels, Blood-brain barrier, Neuroinflammation, Lipopolysaccharide, p-glycoprotein, Cytokine receptor, IL15, TNF
This content is only available via PDF.
© 2010 S. Karger AG, Basel
2010
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.